BiotechTube

Ipilimumab + Nivolumab

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Mar 16, 2015 → Oct 16, 2024

NCT ID
NCT02388906

About Ipilimumab + Nivolumab

Ipilimumab + Nivolumab is a phase 3 stage product being developed by Ono Pharmaceutical for Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02388906. Target conditions include Melanoma.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)
✅dabrafenib + trametinibNovartisApproved
✅ZelborafRocheApproved
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02388906Phase 3Completed

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
Binimetinib Oral TabletBiotrialPhase 1
15
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
32
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
23
FYB206 + KeytrudaFormycon AGPhase 1
23
PLX3397Daiichi SankyoPre-clinical
26
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
24
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
DS-8273a + NivolumabDaiichi SankyoPhase 1
29
PLX3397 + vemurafenibDaiichi SankyoPhase 1
21
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
42
CP-461Astellas PharmaPhase 2
27
YM155Astellas PharmaPhase 2
35
YM155 + DocetaxelAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
E7080EisaiPhase 1
29
lenvatinib + pembrolizumabEisaiPhase 2
35
MORAb-004 (monoclonal antibody)EisaiPhase 2
35
Pembrolizumab + LenvatinibEisaiPhase 2
39
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
32